Renhuang Pharmaceuticals, Inc. (OTC:RHGP) reported that it has successfully produced lyophilized syringin powder, a new form of a successful traditional Chinese medication. Syringin is a glucoside found in the bark of the lilac (Syringa) that is extracted as a white crystalline substance; lyophilized means that the substance is freeze-dried.
The substance is a powder injection intended to treat depression and fatigue. The powder is extracted from Acanthopanax (also known as Siberian Ginseng), a product that already supplies 53% of Renhuang’s revenues. Renhuang also controls 70% of China’s production of the herb. The powder is 90% pure, which meets the criteria of the SFDA.
Renhuang intends to put the substance into clinical trials to prove safety and efficacy. Renhuang hopes that the new medication will provide relief for depression and fatigue without causing the negative side effects of synthetic anti-depressants.
Renhuang has begun filing for an invention patent for the substance. The company expects the SFDA to classify it as a “Class One” new drug, the designation for a major breakthrough.
Renhuang has also bought prime time advertising slots on China Central Television Station [CCTV] in 2008 to increase the brand recognition of its products. Some of the advertising will occur during the Beijing Olympics this summer.
Located in Harbin, Heilongjiang province, in Northeast China, Renhuang produces three major product lines: Acanthopanax-based natural medicinal products, Shark Power Health Care series (a natural marine biology product), and Traditional Medical Products.